US FDA Urged To Rethink Warning Letters To Avoid ‘Collateral Damage’

Industry attorneys worry US agency is not considering late responses to adverse inspection reports before issuing warnings, and that letters sometimes go beyond the recommendations laid out in existing FDA guidance